OmniComm Systems, Inc. Continues Its Rapid Expansion by Opening a New Office in Monmouth Junction, NJ

FORT LAUDERDALE, FL--(Marketwire - November 19, 2009) -

OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC and eClinical marketplace, announced today that it has opened a new office in Monmouth Junction, NJ. The new location, situated equal distance between Princeton and Rutgers Universities, was chosen in part for its proximity to the Route One technology and pharmaceutical research corridor.

“We are very pleased with our new office space,” said Kenneth Light, Senior Vice President Professional Services and General Manager of the New Jersey office. “We serve the pharmaceutical, biotech, device and CRO industries and this latest location allows us to better serve our customers situated here in the Northeast.” Mr. Light added, “This is a full service location offering training, project management, software development, customer care, and consulting services. In addition to our very experienced team already located in New Jersey, this office gives us access to the broad talent pool of clinical research and technology professionals located in the area. 2009 has been a year of tremendous successes and growth for OmniComm. Our new office is testimony that we are continuing to implement our business strategy which includes increasing our U.S. footprint to better serve our customers with our e-clinical solutions and services.”

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL, and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company’s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company’s financial results can be found in the Company’s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.